One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

The following is a summary of “Efficacy and safety of PD-1/PD-L1 inhibitor monotherapy or combination therapy versus platinum-based chemotherapy as a first-line treatment of advanced urothelial cancer ...

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy. Now, the company has made a move to try to make sure it isn ...

Incyte's first attempt to get FDA approval for its PD-1 inhibitor Zynyz for squamous cell carcinoma of the anal canal (SCAC) was knocked back by the FDA, but new data could get the programme back ...

Technologies announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU ...

In this randomized controlled trial, female patients with bacterial vaginosis (BV) had lower recurrence rates when their male ...

In seven patients with Danon disease, a single infusion of adeno-associated virus serotype 9 carrying transgene LAMP2B ...

This randomized controlled trial conducted in Kenya and Uganda assessed whether fractional doses of the 17D-204 yellow fever ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...